NGeneBio엔젠바이오

NGeneBio's shares have fallen sharply over the past year, and its market value is now about ₩15B amid heavy losses and a regulatory warning.

NGeneBio sells genomic diagnostic products and analysis software, mainly to hospitals in Korea, and is adding AI-based analysis. Its trailing twelve-month revenue is about ₩41.8B, but operating losses of about ₩6.3B and negative free cash flow of about ₩6.0B continue, with cash of about ₩3.0B. The share price closed at ₩937 on 2026-10-16, down about 81% over one year.

What stands out

• Revenue rose sharply in 2025 to about ₩21.2B from ₩5.7B in 2024, but operating losses were still about ₩8.3B that year.
• Trailing twelve-month figures to H1 2026 show an operating margin of -15.1% and a net margin of -12.1%, which is an improvement from 2025's -39% operating margin.
• Liabilities are about 278% of equity, and the data shows no borrowings figure, so the balance sheet is stretched but the debt level is not specified.
• Recent filings include a rights offering, convertible bond activity, a CEO change on 2026-09-15, and a notice on potential designation as an administrative issue because market capitalization is below ₩20B.
• Trading flows over the last 20 days show retail investors net sellers of about ₩20.0M, while foreign investors were net buyers of about ₩10.0M; foreign ownership is about 0.1%.
• The data includes no recent news headlines and no analyst ratings or forecasts.

What to watch

• Whether the exchange proceeds with the administrative issue designation tied to market capitalization below ₩20B, as flagged in the 2026-09-22 notice.
• Next periodic financial results, to see whether operating losses narrow and cash burn eases from current levels.
• Dilution effects from the rights offering and convertible bonds, and any further filings on share issuance.